30 closest matches · ranked by relevance
Papillomavirus Infections
Primary: Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7 — 96.97; 99.05; 99.05; 99.05 percentage of participants
HPV Infections
Primary: Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus…
HPV Infections
Primary: Measure Serious Adverse Experiences, Systemic Adverse Experiences Occurring Within 14 Days After Vaccination, and Injection-site Complaints Occurring Day 1 Through Day 5…
Cervical Cancer · Cervical Intraepithelial Neoplasia · Adenocarcinoma in Situ
Primary: Combined Incidence of Cervical Intraepithelial Neoplasia (CIN) 2/3 or Worse Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 — 0.0 Cases per 100 person-years…
Genital Warts · Anal Cancer · Anal Intraepithelial Neoplasia
Primary: Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine — 782.0; 703.9; 568.9; 616.7 milli Merck Units/mL — p=<0.001
Human Papilloma Virus · Cervical Cancer · Vulvar Cancer
Primary: Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase A — 1273.3; 2203.0; 4784.7; 1991.6 mMU/mL
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Primary: Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA) — 975.2; 686.6; 807.4; 580.2…
Human Papillomavirus-Related Cervical Carcinoma
Primary: Number Seropositive for HPV16 at 36 Months — 538; 366 Participants
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Infections, Papillomavirus
Primary: Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)…
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants
Infections, Papillomavirus
Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical…
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies — 36791.8; 10053.1; 16486.9; 2257.9 titer
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type — 787.8; 638.4; 598.7; 453.5 mMU/mL — p=< 0.001
Human Papillomavirus
Primary: B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) — 0.61; 0.94; 0.36; 0.08 % of memory B cells that are Ag-specific
Infections, Papillomavirus
Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) — 0.5; 15.8 Cases per 10,000 person-years follow-up — p=<0.0001
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001
Infections, Papillomavirus
Primary: Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies — 5844.6; 10500.9; 7741.6; 13045.3 EL.U/mL
Papillomavirus Infections
Primary: Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 — 100.0; 100.0; 100.0; 100.0 Percentage of Participants
Cervical High Grade Squamous Intraepithelial Lesion
Primary: Cervical HSIL — 46; 39 Participants — p=.29
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months) — 416; 417 Participants — p=<0.001
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants
Influenza
Primary: Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or With Trivalent Influenza Vaccines With Corresponding…
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 337; 342; 345; 346…